To make disease-modifying first-in-class treatments available to patients suffering from conditions such as cancer, cognitive decline and fibrosis.

Medibiofarma discovers and develops new chemical entities (NCEs) with clinical proof-of-concept  data in human patients

Medibiofarma focuses internal resources in the followings areas:

• Drug Design
• Medicinal and Synthetic Chemistry
• In Vitro Pharmacology
• Intellectual Property
• Clinical Trials
• Business Development

The remaining activities for the full characterization and nomination of a development candidate, such as in vivo pharmacology, toxicology and IND-enabling studies  are carried out through partnerships with several companies (CROs), Research Centers and Universities.